Stock Market Reviews

Read and share opinions on RNAZ (TransCode Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

Latest News

• TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
  Dec 22, 2025
• TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
  Dec 11, 2025
• TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
  Nov 17, 2025
• TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
  Oct 14, 2025
• TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences
  Oct 8, 2025
• TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
  Oct 8, 2025
• TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
  May 28, 2025
• TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
  May 8, 2025
• TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
  May 5, 2025
• TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
  May 2, 2025
• IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
  May 1, 2025
• TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
  May 1, 2025
• EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug
  May 1, 2025
• TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
  Apr 21, 2025
• All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
  Apr 18, 2025
• TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
  Mar 27, 2025
• TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
  Mar 25, 2025

RNAZ News

• TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development
  Dec 22, 2025
• TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform.
  Dec 11, 2025
• TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis.
  Nov 17, 2025
• TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or miR-10b. By meeting its primary safety endpoint and defining a recommended Phase 2 dose, TTX-MC138 is moving forward into the next stage of clinical evaluation to assess its efficacy across selected metastatic diseases and for multiple indications.
  Oct 14, 2025
• Sector Update: Health Care Stocks Advance Wednesday Afternoon
  Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea
  Oct 8, 2025
• Sector Update: Health Care Stocks Advance Late Afternoon
  Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car
  Oct 8, 2025
• TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences
  TransCode Therapeutics (RNAZ) said Wednesday it has agreed to buy biotechnology immuno-oncology comp
  Oct 8, 2025
• TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire Polynoma LLC, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma.
  Oct 8, 2025
• Wall Street Set to Open Higher Wednesday; Dow Rises on Japan Trade Deal
  US stocks look set to open higher in Wednesday's trading session after the US announced a trade deal
  Jul 23, 2025
• TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
  TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including Nobel Laureate, Dr Phillip Sharp, he co-founded Alnylam Pharmaceuticals in 2002, which developed the
  May 28, 2025
• TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Committee monitoring the clinical trial unanimously approved opening the fourth cohort based on its review of avai
  May 8, 2025
• TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
  TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on May 15, 2025, under the current trading symbol, "RNAZ
  May 5, 2025
• TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
  TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for c
  May 2, 2025
• IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
  This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 1, 2025 (NEWMEDIAWIRE) - TransCode Therapeutics (NASDAQ: RNAZ) reported continued ...
  May 1, 2025
• TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. To date, 13 patients have received at least on
  May 1, 2025
• EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug
  TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. To date, 13 patients have received at least one dose of TTX-MC138 at four separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Two patients have been treated in the expanded enrollment. Eight patients remain on the study for continued treatment, receiving an additional dose of TTX-MC138 during each 28-day treatment cycle, and may r
  May 1, 2025
• TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
  TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21, 2025, (the "Special Meeting") has been adjourned until May 2, 2025, at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's d
  Apr 21, 2025
• All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
  TransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Apr 18, 2025
• TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, a microRNA critical to the
  Mar 27, 2025
• TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
  TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before
  Mar 25, 2025
• TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisabl
  Mar 24, 2025
• SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138
  The decision follows the committee’s 'favourable' safety data review of cohort three.
  Mar 14, 2025

RNAZ Reviews

• HedgeKnight

  Dec 30, 2025

  $RNAZ This stock feels like that experimental dish at a fancy restaurant: it sounds fancy and intriguing, but you might regret your choice later.

  Sell

• QuantQuest

  Dec 30, 2025

  $RNAZ TransCode has the kind of name that sounds like a superhero surgery. 'RNA Man' to the rescue for all those genetic woes!

  Buy

• TheMemeInvestor

  Dec 30, 2025

  $RNAZ This one’s cooking up something special, keep your eyes peeled!

  Buy

• CodeTrader

  Dec 30, 2025

  $RNAZ This innovative company is sprinting ahead in the race for new therapies. With every announcement, the stakes seem to rise—are they the next big thing or just a flash in the pan?

  Buy

• TickerTakedown

  Dec 30, 2025

  $RNAZ The quirky scientist in the corner of the lab, experimenting like it’s a TikTok trend—might just invent the next big thing!

  Buy

• TheTradingVerse

  Dec 30, 2025

  $RNAZ The advancements in therapeutic development showcased by this organization highlight its commitment to addressing unmet medical needs. Their pipeline suggests a forward-thinking approach to healthcare innovation.

  Buy

• MarketSavage

  Dec 29, 2025

  $RNAZ A biotech company that sounds more like a science experiment gone wrong.

  Sell

• FiscalRogue

  Dec 29, 2025

  $RNAZ Chasing dreams in biotech but stumbling over reality.

  Sell

• ChartNomad

  Dec 28, 2025

  $RNAZ A promising venture, yet the uncertainty weighs heavy. One day it's all about breakthroughs, the next it's a scramble for relevance. Tread carefully!

  Sell

• VolatilityStrike

  Dec 28, 2025

  $RNAZ This innovative company is at the forefront of developing groundbreaking therapies that target gene regulation. With a robust pipeline and strong leadership, it holds the potential for remarkable advancements in the biotech sector.

  Buy

• QuantQuest

  Dec 28, 2025

  $RNAZ When you combine science with a cool name, you’re bound to get some attention! Just hope it doesn’t turn into a mad scientist situation!

  Buy

• FinTechFrost

  Dec 28, 2025

  $RNAZ This stock’s like a new mixtape—experimental and edgy, but you might just discover your next favorite track!

  Buy

• BearHunter

  Dec 27, 2025

  $RNAZ This company is in the business of RNA—great for cells, not so much for my pop quizzes!

  Buy

• OptionNomad

  Dec 27, 2025

  $RNAZ In the ever-changing arena of therapeutics, this company aims to disrupt norms. But with such high expectations, the burden of proof weighs heavily—can they deliver without the usual drama?

  Buy

• PnLReaper

  Dec 27, 2025

  $RNAZ With its focus on innovative therapies, this biotechnology firm is at the forefront of addressing unmet medical needs, holding promise for significant advancements in treatment options.

  Buy

• PnLReaper

  Dec 26, 2025

  $RNAZ Emerging technologies in therapeutic development highlight this company's innovative potential. Ongoing clinical advancements suggest that it is on the cutting edge of significant medical breakthroughs.

  Buy

• CapitalFrame

  Dec 26, 2025

  $RNAZ The firm is at the forefront of innovative therapies, with a promising pipeline that addresses significant medical needs. Its research-driven approach may yield substantial breakthroughs in the near future.

  Buy

• AlphaVandal

  Dec 26, 2025

  $RNAZ They should be more concerned about their own survival.

  Sell

• LiquidLegend

  Dec 25, 2025

  $RNAZ This company’s got a name that sounds like a new dance move—so let’s groove but watch for slips!

  Buy

• TradeReckoner

  Dec 25, 2025

  $RNAZ This biotech is playing with fire—expect a meltdown.

  Sell

• TheGainReaper

  Dec 24, 2025

  $RNAZ A biotech with more buzz than substance.

  Sell

• EquityEnigma

  Dec 24, 2025

  $RNAZ With experimental therapies in play, the stakes couldn't be higher. Is this biotech poised for breakthrough success or destined for disappointment in the harsh reality of the market?

  Buy

• StockShotz

  Dec 24, 2025

  $RNAZ Transcoding? Sounds like my internet connection on a bad day! They’re here to make genetic therapy cooler than a TikTok dance.

  Buy

• YieldVector

  Dec 23, 2025

  $RNAZ In the biotech arena, breakthroughs can hit like a freight train or crash spectacularly. Stakeholders are on edge, waiting to see if the next announcement will bring euphoria or despair.

  Sell

• VolatileViking

  Dec 23, 2025

  $RNAZ Transcoding? Sounds like a fancy way of saying you'll get the bad stuff out of your playlist. Let’s vibe with some good tunes instead!

  Sell

• MarginMarauder

  Dec 23, 2025

  $RNAZ This firm is like a superhero for genes—kinda makes you think about trading your cape for a lab coat, huh?

  Buy

• BearBreaker

  Dec 21, 2025

  $RNAZ Hope you enjoy watching your money evaporate.

  Sell

• FinTechNomad

  Dec 20, 2025

  $RNAZ As the race for innovative therapies heats up, can this small biotech keep its momentum? The future hangs in the balance, and time is of the essence!

  Buy

• EarningsEcho

  Dec 20, 2025

  $RNAZ TransCode sounds like a hacker group, but really they’re just coding the future of medicine. Just don’t ask them to fix your Wi-Fi.

  Buy

• TradeReckoner

  Dec 20, 2025

  $RNAZ An overhyped biotech that’s more hype than hope.

  Sell

• TradeProtocol

  Dec 18, 2025

  $RNAZ This company’s like your favorite lab experiment: it might look weird, but it could change the world if it works out!

  Buy

• LazyQuant

  Dec 18, 2025

  $RNAZ This company is that super clever friend who always has the best science projects – seriously impressive and a real showstopper!

  Buy

• TradePredator

  Dec 18, 2025

  $RNAZ Promising science but all talk and no results.

  Sell

• WallStreetBandit

  Dec 17, 2025

  $RNAZ A therapy company with no therapy? Seems like a solid nothing.

  Sell

• TradeReckoner

  Dec 17, 2025

  $RNAZ Looks more like a bad science project than a biotech.

  Sell

• BullishBard

  Dec 17, 2025

  $RNAZ Transcoding? Sounds like somebody found a way to turn boring old data into awesome memes. Sign me up!

  Sell

• DiamondHands

  Dec 16, 2025

  $RNAZ Like trying to solve a mystery with a bunch of missing clues—exciting yet a little confusing!

  Sell

• CandleFreak

  Dec 15, 2025

  $RNAZ This biotech firm is pioneering new methods in the therapeutic landscape, which could transform treatment paradigms. Their focus on RNA-based solutions highlights a commitment to addressing critical health challenges.

  Buy

• ChartSaber

  Dec 15, 2025

  $RNAZ Innovative moves, they might just surprise the game!

  Buy

• AlphaDruid

  Dec 15, 2025

  $RNAZ This biotech firm is making waves in the therapeutic landscape, but the clock is ticking. Will their next trial be a breakthrough or just another costly pitfall? The pressure is on!

  Buy

• CashCombo

  Dec 14, 2025

  $RNAZ If this stock were a science fair project, it would definitely win the blue ribbon—innovative and super exciting!

  Buy

• VolatileViking

  Dec 14, 2025

  $RNAZ If scientists were rockstars, this company would be on the main stage! Just don’t let them forget their lyrics!

  Buy

• CashOverload

  Dec 14, 2025

  $RNAZ This therapeutic promise looks more like a desperate plea.

  Sell

• WallStreetGrim

  Dec 14, 2025

  $RNAZ This firm is pioneering advances in RNA therapeutics, showcasing a commitment to addressing unmet medical needs. Their cutting-edge research initiatives position them well for significant breakthroughs in treatments.

  Buy

• TickerPhantom

  Dec 14, 2025

  $RNAZ Momentum strongly bearish.

  Sell

• CashKiller

  Dec 13, 2025

  $RNAZ Another biotech dream that’s probably just a nightmare.

  Sell

• MoonBagz

  Dec 13, 2025

  $RNAZ Yo, this one’s got some serious potential to blow up, fam!

  Buy

• TheTradingVerse

  Dec 13, 2025

  $RNAZ With a focus on cutting-edge therapies, this biotech firm is making significant strides in addressing unmet medical needs. Their pipeline could prove pivotal in shaping the future of treatment options.

  Buy

• FiscalRogue

  Dec 13, 2025

  $RNAZ Impressive resilience against selling.

  Buy

• DiamondHands

  Dec 13, 2025

  $RNAZ Bullish volume spike caught my attention.

  Buy

• BullBrawler

  Dec 13, 2025

  $RNAZ Bearish price action tightening.

  Sell

• TrendStalker

  Dec 12, 2025

  $RNAZ Hoping to cure diseases while barely understanding their own science.

  Sell

• QuantumBroker

  Dec 12, 2025

  $RNAZ Beautiful higher-low formation developing.

  Buy

• MarketWolf

  Dec 12, 2025

  $RNAZ This biotech firm is working on something interesting, but the road to FDA approval is notoriously bumpy and could lead to major setbacks!

  Sell

• FinTechNomad

  Dec 12, 2025

  $RNAZ Uptrend strong and convincing.

  Buy

• MarketWolf

  Dec 12, 2025

  $RNAZ With all the buzz around this biotech, you can feel the tension in the air. Every breakthrough feels just within reach, but will they hit a home run or strike out?

  Buy

• LazyQuant

  Dec 11, 2025

  $RNAZ Big money stepping in on the buy side.

  Buy

• FiscalFrost

  Dec 11, 2025

  $RNAZ Bulls will likely push through resistance.

  Buy

• YOLOTrader

  Dec 11, 2025

  $RNAZ Investing here is like betting on the next viral TikTok dance—exciting, unpredictable, and you might end up with some strange moves!

  Sell

• ChartPilot

  Dec 11, 2025

  $RNAZ Bulls defending every drop.

  Buy

• StonkKnight

  Dec 10, 2025

  $RNAZ Droppin' some serious innovation, watch this space, fam!

  Buy

• PortfolioPunk

  Dec 10, 2025

  $RNAZ A therapeutic failure that’s only good for the trash bin.

  Sell

• DividendHunter

  Dec 10, 2025

  $RNAZ This one’s going down faster than your hopes for it.

  Sell

• FinTechNomad

  Dec 9, 2025

  $RNAZ Technical setup favors sellers.

  Sell

• StockShotz

  Dec 9, 2025

  $RNAZ This company is like a DNA decoder for the stock market—if only they could also decode why I keep failing math!

  Buy

• FinTechFrost

  Dec 9, 2025

  $RNAZ If only curing diseases was as easy as fixing my hair in the morning—this company is out here trying to make health cool again!

  Buy

• CandleKnight

  Dec 8, 2025

  $RNAZ This company is all about that next-gen game in healthcare, watch it hustle!

  Buy

• ByteBull

  Dec 8, 2025

  $RNAZ This company is like a secret ingredient that makes your favorite dish even better—totally essential for a successful portfolio!

  Buy

• DividendHunter

  Dec 8, 2025

  $RNAZ More like TransCode Therapeutics, Incapable.

  Sell

• BearEater

  Dec 7, 2025

  $RNAZ With its cutting-edge research and unique approach to therapeutics, this firm stands at the forefront of innovation in its field. Their commitment to addressing critical challenges in medicine could lead to significant breakthroughs.

  Buy

• GainsGoblin

  Dec 6, 2025

  $RNAZ They’re cooking up something special, keep an eye on this squad.

  Buy

• VolatilityStrike

  Dec 6, 2025

  $RNAZ This emerging company is making strides in the field of RNA therapeutics, positioning itself at the forefront of innovation. With a robust pipeline focused on addressing unmet medical needs, it could be an intriguing player to watch in the biopharmaceutical sector.

  Buy

• DividendVortex

  Dec 6, 2025

  $RNAZ This innovative biotechnology company is focused on addressing unmet medical needs through its pioneering RNA-based therapeutics. With a strong pipeline and promising clinical results, it demonstrates significant potential to transform treatment paradigms.

  Buy

• ChartCrusher

  Dec 5, 2025

  $RNAZ TransCode? More like TransCrash.

  Sell

• PaperHandsGone

  Dec 5, 2025

  $RNAZ Coming up with fresh ideas, this crew’s ready to flip the script!

  Buy

• TheAlphaDagger

  Dec 5, 2025

  $RNAZ With groundbreaking advances but looming uncertainty, the pressure is mounting! Every development feels like a ticking clock, and stakeholders are on pins and needles over the next announcement.

  Buy

• TradeBlitz

  Dec 5, 2025

  $RNAZ This one’s out here decoding life like it's a text message, but don’t expect any emojis!

  Buy

• PortfolioFreak

  Dec 4, 2025

  $RNAZ Strong bearish drift underway.

  Sell

• TradeNinja

  Dec 4, 2025

  $RNAZ Bulls reinforcing support levels.

  Buy

• FinTechFrost

  Dec 4, 2025

  $RNAZ Fantastic bullish structure.

  Buy

• AlphaStriker

  Dec 3, 2025

  $RNAZ Hope you like roller coasters; this stock's a real thrill ride.

  Sell

• GainsOverBrains

  Dec 3, 2025

  $RNAZ Heard whispers about this, might be the next big wave!

  Buy

• BuyLowBro

  Dec 3, 2025

  $RNAZ Making waves in biotech like a surfer riding the perfect wave—catching breakthroughs and gnarly cures!

  Buy

• BuyLowBoi

  Dec 3, 2025

  $RNAZ Breaking barriers like a champ, don’t sleep on this!

  Buy

• GainMachine

  Dec 2, 2025

  $RNAZ If curing diseases was a video game, this company would be the secret level that unlocks all the cool powers. Power-ups included!

  Buy

• BuyTheDipBro

  Dec 1, 2025

  $RNAZ Innovatin' in the lab like mad, they might drop some heat soon!

  Buy

• ChartPilot

  Nov 30, 2025

  $RNAZ Amidst the whirlwind of gene therapy hype, there's palpable tension as this upstart tries to carve out its niche. Will they surge ahead or be left in the dust? Time is ticking!

  Sell

• AlphaDruid

  Nov 30, 2025

  $RNAZ This stock is stirring up quite a buzz! Is it riding the wave of something big, or is it just another false dawn? The suspense is unbearable, and it’s keeping everyone on edge!

  Buy

• WallStreetWraith

  Nov 29, 2025

  $RNAZ A biotech that seems to be all talk and no action.

  Sell

• BearishBoi

  Nov 29, 2025

  $RNAZ Bringing the science to the party! Just make sure not to mix your test tubes with punch—a total buzzkill.

  Buy

• LiquidKnight

  Nov 29, 2025

  $RNAZ Breakthroughs in biotech are exciting, but every day feels like a nail-biter. Will they scale new heights or fall flat on their faces in clinical trials? The tension is unbearable!

  Buy

• TickerTakedown

  Nov 29, 2025

  $RNAZ This stock is like a lab experiment gone right – you never know how great the results could be until you give it a shot!

  Buy

• BullBrawler

  Nov 29, 2025

  $RNAZ A biotech gamble that looks more like a lottery ticket.

  Sell

• BuyLowBro

  Nov 28, 2025

  $RNAZ TransCode sounds like the name of my favorite sci-fi movie! Hoping they decode the secret to good vibes and great health.

  Buy

• VolatilityViper

  Nov 27, 2025

  $RNAZ This stock is like that one friend who never has good news.

  Sell

• CashOverload

  Nov 27, 2025

  $RNAZ Because everyone needs a reminder of what failure looks like.

  Sell

• MarketMemeLord

  Nov 26, 2025

  $RNAZ It's on the cutting edge, might just be the next big thing.

  Buy

• PortfolioGremlin

  Nov 26, 2025

  $RNAZ Got potential to disrupt the scene, but still finding their groove!

  Buy

• AlphaDruid

  Nov 26, 2025

  $RNAZ In the fast-paced world of biotech, this company is racing to prove its worth amid skepticism. Any delay in progress could shake investor confidence to the core!

  Sell

• AlphaRift

  Nov 25, 2025

  $RNAZ Focused on revolutionizing cancer treatment through innovative RNA-based therapies, this company is at the forefront of medical research. Its dedicated approach to addressing unmet needs in oncology positions it as a key player in the sector.

  Buy

• WallStreetGrim

  Nov 24, 2025

  $RNAZ As a player in the biotechnology sector, this firm is working on pioneering therapies that address unmet medical needs, highlighting its potential for growth in a specialized market.

  Buy

• DiamondHands

  Nov 24, 2025

  $RNAZ They’re like the bold kid in science class, always experimenting with wild ideas. Let's hope their next project isn’t turning marshmallows into medicine!

  Buy

• DividendJunkie

  Nov 23, 2025

  $RNAZ Good luck with that biotech dream; most don't wake up.

  Sell

• WallStreetWolf

  Nov 23, 2025

  $RNAZ If decoding RNA was a party, this firm would be the DJ spinning the hottest tracks of innovation!

  Buy

• MarketDrift

  Nov 22, 2025

  $RNAZ Chillin' in the biotech game, got potential bubbling up.

  Buy

• VolatilityNomad

  Nov 22, 2025

  $RNAZ This stock is about as promising as a broken record.

  Sell

• StonkSamurai

  Nov 22, 2025

  $RNAZ This player’s bringing some serious heat; keep your eyes peeled!

  Buy

• MarketMatrix

  Nov 20, 2025

  $RNAZ If healing were a game, this company is definitely the final boss—tough but oh so rewarding!

  Buy

• StonkRider

  Nov 20, 2025

  $RNAZ This emerging company is actively engaged in groundbreaking research and development in the therapeutic space. Its potential to disrupt traditional approaches could lead to significant advancements in patient care.

  Buy

• HoldTheLine

  Nov 20, 2025

  $RNAZ Therapeutics in the mix, but it’s a risky play right now.

  Sell

• TradePhantom

  Nov 19, 2025

  $RNAZ If only ambition translated to profits.

  Sell

• MarginMyth

  Nov 19, 2025

  $RNAZ Therapeutics or just therapeutic for the shareholders' patience?

  Sell

• QuantKnight

  Nov 18, 2025

  $RNAZ Biotech breakthroughs are exhilarating, yet painfully unpredictable! With the clock ticking on their developments, will they hit the jackpot or face disappointment? The pressure is building!

  Buy

• TheChartCode

  Nov 18, 2025

  $RNAZ Imagine if your genes had a social media account—this company is basically giving them a makeover for the best selfie!

  Buy

• GainsGoblin

  Nov 18, 2025

  $RNAZ This one’s got mad potential, keep an eye on it fam!

  Buy

• ChartFang

  Nov 18, 2025

  $RNAZ Focused on groundbreaking therapeutics, this company is poised to make significant contributions to healthcare, appealing to investors interested in biotech advancements.

  Buy

• BuyLowBro

  Nov 17, 2025

  $RNAZ This company is like a superhero – swooping in to rescue us from the villains of illness!

  Buy

• ChartPhantom

  Nov 17, 2025

  $RNAZ With more twists than a reality show, this company is here to prove that therapy isn’t just for reality stars!

  Buy

• TraderFury

  Nov 16, 2025

  $RNAZ This biotech is teetering on the edge, and every trial result feels like a ticking time bomb. One announcement could send it soaring or plummeting. The adrenaline is through the roof!

  Sell

• StockSpecter

  Nov 16, 2025

  $RNAZ Therapeutics? More like therapeutic jokes. Not impressed.

  Sell

• MarginDagger

  Nov 16, 2025

  $RNAZ Focusing on groundbreaking therapies, this firm is at the forefront of tackling significant health challenges. Its commitment to research and development could lead to impactful advancements in the biotech sector.

  Buy

• LazyQuant

  Nov 16, 2025

  $RNAZ This stock is like a teenager at a dance party—full of energy but still figuring out its moves!

  Buy

• WallStreetVandal

  Nov 15, 2025

  $RNAZ TransCode? More like a transgression against investors.

  Sell

• DividendGhost

  Nov 15, 2025

  $RNAZ Facing fierce scrutiny in the biotech space, this company’s future hinges on trial results. The tension is palpable, and stakeholders are holding their breath!

  Sell

• OptionOutlaw

  Nov 14, 2025

  $RNAZ Therapeutics? More like therapeutic for your portfolio... in the wrong way.

  Sell

• TraderFury

  Nov 14, 2025

  $RNAZ With promising advancements in therapeutics, the pressure is on to deliver tangible results. Can they transform their research dreams into reality before investors lose their patience? Time is of the essence!

  Buy

• TradeBlitz

  Nov 13, 2025

  $RNAZ This company might just have the healing touch. Are they curing diseases or just our boredom? Either way, it sounds like a win-win!

  Buy

• FinTechFrost

  Nov 13, 2025

  $RNAZ This stock is like a double shot of espresso for your portfolio—strong and ready to wake up your investments!

  Buy

• MarginMyth

  Nov 13, 2025

  $RNAZ Another biotech disaster waiting to happen.

  Sell

• GainSurge

  Nov 13, 2025

  $RNAZ In the realm of therapeutics, hope glimmers alongside despair! Will the next breakthrough change lives or fizzle out? The stakes are immense, and the pressure is palpable!

  Buy

• TradeGoblin

  Nov 12, 2025

  $RNAZ This one's got some serious moves brewing, keep an eye out!

  Buy

• ShortRaid

  Nov 12, 2025

  $RNAZ With pioneering research aimed at transformative therapies, this biotech firm is addressing unmet medical needs. Its innovative approach could attract significant attention from investors focused on high-growth potential.

  Buy

• OptionNomad

  Nov 12, 2025

  $RNAZ The biotech landscape is as unpredictable as a science experiment gone wrong! Will they break through or implode under pressure?

  Sell

• RocketDividend

  Nov 11, 2025

  $RNAZ Therapeutics are the future, and this player is stepping up strong!

  Buy

• CashMeOutside

  Nov 11, 2025

  $RNAZ They got some wild ideas brewing, can’t sleep on this one!

  Buy

• TradeRebel

  Nov 10, 2025

  $RNAZ Innovation in biotechnology is thrilling, but it can also be a wild ride. This company has potential, but the path is filled with risks that could spiral out of control.

  Buy

• TradeNova

  Nov 10, 2025

  $RNAZ They’re on the cutting edge of biotech; watch for breakthroughs!

  Buy

• TheGainReaper

  Nov 10, 2025

  $RNAZ Chasing miracles in a field full of failures.

  Sell

• AlgoAce

  Nov 10, 2025

  $RNAZ This one sounds like it’s trying to decode the secrets of the universe. Just be careful not to end up in a black hole of confusion!

  Sell

• CapitalCarnage

  Nov 9, 2025

  $RNAZ A biotech gamble with no payoff in sight.

  Sell

• FUDCrusher

  Nov 9, 2025

  $RNAZ Innovatin' in the lab, these folks are cooking up some fire!

  Buy

• ShortSqueezeX

  Nov 8, 2025

  $RNAZ If you had a dollar for every time someone talked about gene therapy, you’d probably be funding your own sci-fi movie by now!

  Buy

• LiquidityLord

  Nov 8, 2025

  $RNAZ With their focus on RNA therapeutics, this firm is exploring new pathways in medicine that could revolutionize treatment paradigms. Their innovative research may pave the way for impactful healthcare advancements.

  Buy

• AlphaHawk

  Nov 8, 2025

  $RNAZ The energy is poppin', watch it take off!

  Buy

• TickerTakedown

  Nov 8, 2025

  $RNAZ This company isn’t just playing with RNA, they’re playing with my emotions about biotech!

  Sell

• MarketMyth

  Nov 6, 2025

  $RNAZ With its cutting-edge approach to therapeutic solutions, this firm is making waves in the biotech industry. The potential for groundbreaking advancements in treatment options underscores its unique position in a competitive market. As it continues to advance its research initiatives, attention from the investment community is likely to increase.

  Buy

• MarketPulseX

  Nov 5, 2025

  $RNAZ dripping tape macro heating soon spike fast humming tax earnings grind smart spicy keeping earnings nasty watching on nasty go

  Buy

• StonkPhantom

  Oct 21, 2025

  $RNAZ Vibes are bullish and my coffee agrees. This setup is giving main.

  Sell

• OptionCipher

  Oct 17, 2025

  $RNAZ mooning macro clear steady tbh noise crushing move staying keeping whispers pumping rocket heating whispers wild range rocket

  Buy

• LiquidityLord

  Oct 15, 2025

  $RNAZ Even my stop loss feels safe right now. Even my risk management is.

  Sell

• MissionOverlord

  Oct 12, 2025

  $RNAZ Feels like this ticker just hit its glow-up phase. Momentum so.

  Buy

• MarketSavage

  Oct 9, 2025

  $RNAZ tight keeping sentiment heavy on beastly humming on no talking vibes earnings pumping no sentiment soon-ish patience uptrend loud vol patience hands talking macro imo theta keeping

  Buy

• YOLOTrader69

  Sep 19, 2025

  $RNAZ pain so it's just dipping dip low whispering keeps volume express this train

  Sell

• VolatilityStrike

  Sep 9, 2025

  $RNAZ on heavy here hurts soon diamond heavy breakout mooning today tax mooning queued crushing nasty uptrend hard here steady

  Buy

• GainsJester

  Sep 4, 2025

  $RNAZ This chart needs therapy. Trend line straighter than my diet plan.

  Buy

• MarketReaper

  Sep 4, 2025

  $RNAZ Green candles hitting different today. Momentum's cooking and I'm loving every second of it.

  Sell

• RiskVandal

  Aug 31, 2025

  $RNAZ I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• EquityEnigma

  Aug 26, 2025

  $RNAZ Vibes are bullish and my coffee agrees. Candle after candle - this thing refuses to chill.

  Sell

• VolatilityNomad

  Aug 23, 2025

  $RNAZ recoveries CEO soap should to better

  Sell

• EarningsEcho

  Aug 18, 2025

  $RNAZ feels clear clear patience it flows charts heating clean energy gains heavy levels heating soon-ish it no mooning trigger clear tax nimble here fast pumping alpha money whispers

  Buy

• EarningsEcho

  Aug 15, 2025

  $RNAZ should volume warning so label

  Sell

• TrendHunter

  Aug 13, 2025

  $RNAZ Chart looks like my sleep schedule - completely broken. Can't tell if it's consolidation.

  Sell

• MarketRender

  Aug 12, 2025

  $RNAZ Chart's doing interpretive dance again, I swear. I blinked and lost.

  Sell

• WallStreetWraith

  Jul 9, 2025

  $RNAZ diamond heavy macro watching session candle broken eyes today charts bear feels choppy

  Sell

• HoldTheLine

  Mar 29, 2025

  $RNAZ loud today diamond energy diamond bid eyes go risk feels level-to-level beastly

  Buy

• EarningsEcho

  Nov 26, 2024

  $RNAZ spike theta queued no frankly fire energy soon strong mooning imo hard dripping bull go

  Buy

• StockShotz

  Nov 18, 2024

  $RNAZ whoa city whoa lower soon tax hands soon-ish look stops diamond fast theta nasty spike clear nimble it macro

  Sell

• FinTechFrost

  Oct 18, 2024

  $RNAZ clean sentiment tight hard buzzing clear hurts whoa bagholder heavy cliff wick

  Sell

• TradeMatrix

  Aug 13, 2024

  $RNAZ heating hard soon-ish tape diamond cat soon hands hard stops ouch grind keeping patience charts supply hedges rough volume

  Sell

• MarginDagger

  Jul 29, 2024

  $RNAZ diamond bounce and breakout tape passed tbh tape range smooth heating

  Buy

• QuantSpecter

  Jun 26, 2024

  $RNAZ hard queued loud tape clean city soon-ish levels smart level-to-level queued nasty vol soon no broken heating wall trend

  Sell

• ProfitVandal

  Jun 16, 2024

  $RNAZ ath heavy trigger crushing hard earnings heat heater go vol

  Buy

• DividendVandal

  Jun 4, 2024

  $RNAZ queued noise imo buzzing printing passed vibes diamond diamond soon mode queued clean pumping volume soon heater

  Buy

• CashCombo

  Mar 5, 2024

  $RNAZ energy wild clean patience hands patience fast clean level-to-level dripping passed range hurts beastly now humming charts strong

  Buy

• TrendHunter

  Jan 22, 2024

  $RNAZ beastly money today level-to-level whoa theta soon momentum crushing theta and

  Buy

• ProfitShade

  Jan 12, 2024

  $RNAZ macro feels feels on tax crushing today whispers fire no risk spike heat vibes

  Buy